Our partner is a clinical-stage biopharmaceutical company that develops small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases with no approved or effective therapy. Most of their programs are targeting indications in Neurology, Nephrology, and Rare Disease.

This critical hire drove overall medical safety evaluation for global investigational products and clinical development programs. They participated in FDA and other health authority safety interactions and responses with support from the Chief Medical and Regulatory Officers. They were also accountable for all aspects of the global drug safety function, including the development and delivery of a quality Pharmacovigilance system for assigned products and activities.